CJC-1295 vs Sermorelin: Half-Life and Dosing

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with four amino acid substitutions that protect it from enzymatic degradation. It exists in two forms with dramatically different pharmacokinetics. Understanding which form you are using matters enormously because the side effects, dosing schedules, and clinical evidence differ substantially between them.

Sermorelin is a truncated form of natural GHRH, consisting of the first 29 amino acids of the 44-amino-acid endogenous hormone. These 29 amino acids contain the full biological activity needed to stimulate GH release from the pituitary gland.

Sermorelin was previously FDA-approved under the brand name Geref for diagnosis and treatment of growth hormone deficiency in children (Prakash & Goa, BioDrugs, 1999). The manufacturer discontinued it due to production difficulties, not safety concerns. It remains available through compounding pharmacies with a prescription.

Its 10-20 minute half-life means each injection produces a single, sharp GH pulse that mirrors natural pituitary secretion during deep sleep. Walker et al. confirmed that sermorelin preserves the pituitary neuroendocrine axis and actually stimulates endogenous hGH mRNA production (Walker et al., 2006). Sermorelin does not just trigger GH release; it supports the pituitary's capacity to make GH independently. For safety data, see is sermorelin safe. For body composition effects, see sermorelin for fat loss.

Think of GH secretion like a water delivery system. Sermorelin is a garden hose you turn on briefly and shut off. CJC-1295 no-DAC is a sprinkler on a 3-hour timer. CJC-1295 with DAC is a drip irrigation system running for a full week.

Sermorelin's short half-life is both its limitation and its advantage. The limitation: daily injections are required. The advantage: each pulse replicates the body's natural GH secretion pattern. The pituitary normally releases GH in 6-12 bursts per day, with the largest pulse during stage 3-4 sleep. Sermorelin injected before bed amplifies this natural surge without creating continuous elevation.

CJC-1295 with DAC eliminates daily injections but creates continuous GHRH receptor stimulation. This may increase pituitary desensitization risk over time and produces more side effects from sustained GH elevation: water retention, insulin sensitivity changes, and tingling that are harder to manage because the compound remains active for days after each injection.

CJC-1295 wins on raw GH and IGF-1 output. The question is whether more is better for your specific goals.

CJC-1295 (Teichman et al., 2006): 21 healthy adults received a single CJC-1295 DAC dose at 30-60 mcg/kg. GH increased 2-10-fold and remained elevated for 6+ days. IGF-1 rose 1.5-3-fold for 9-11 days. After multiple weekly doses, mean IGF-1 stayed elevated for 28 days (PMID: 16352683).

Sermorelin (Walker et al., 2006; Prakash & Goa, 1999): Sermorelin at 30 mcg/kg produced significant but shorter GH pulses. In pediatric studies, sermorelin increased growth velocity from 3.0 cm/year to 7.0 cm/year over 12 months, confirming clinically meaningful GH stimulation (PMID: 18031173). Walker et al. showed sermorelin preserves the pituitary neuroendocrine axis, supporting long-term GH production capacity (PMID: 18046908).

The tradeoff: CJC-1295 produces higher, more sustained GH and IGF-1. Sermorelin produces more physiologic pulses that preserve pituitary function. For short-term body composition goals, CJC-1295 may be more effective. For long-term GH axis health, sermorelin has the stronger argument.

Each compound requires a different injection schedule and cycle structure.

Sermorelin's once-daily bedtime injection is the simplest protocol. The peptide amplifies your natural nighttime GH pulse and is cleared from your system by morning. CJC-1295 no-DAC demands 2-3 daily injections, the most demanding schedule of the three. CJC-1295 with DAC offers maximum convenience: one or two injections per week.

For reconstitution instructions and volume calculations, use our peptide reconstitution calculator.

Both compounds are well-tolerated GHRH analogs. Neither elevates cortisol or prolactin, distinguishing them from GHRPs like GHRP-6. Side effects are GH-class effects rather than compound-specific toxicities.

Sermorelin has the mildest profile due to its short half-life and physiologic GH pulse pattern. CJC-1295 with DAC has the most pronounced side effects because sustained GH elevation drives more water retention and metabolic effects. For detailed side effect management protocols, see our CJC-1295/ipamorelin side effects guide.

Peptide pricing varies by source, purity, and region. The following ranges reflect compounded pharmacy pricing in the United States as of 2026.

All three options land in a similar monthly range. The hidden cost difference is injection supplies. Sermorelin and CJC-1295 no-DAC require 30-90 syringes per month compared to 4-8 for CJC-1295 with DAC. Bacteriostatic water, alcohol swabs, and sharps disposal add $15-30/month regardless of the compound.

For sourcing information, see where to buy sermorelin. Sermorelin's historical FDA approval means some insurance plans and clinics can prescribe it more readily than research-only CJC-1295.

This is where the two compounds diverge sharply.

Sermorelin was FDA-approved in 1997 under the brand name Geref. It has a documented FDA safety review on record, which gives it a credibility baseline that CJC-1295 lacks. EMD Serono voluntarily discontinued Geref due to manufacturing challenges, not safety signals. Compounding pharmacies legally produce sermorelin as a compounded medication with a valid prescription.

CJC-1295 was developed by ConjuChem Biotechnologies (now dissolved) and progressed through Phase I/II trials but was never submitted for FDA approval. It is classified as a research compound. Compounding pharmacies produce it under the 503B framework.

The 2024 FDA PCAC (Pharmacy Compounding Advisory Committee) meetings addressed compounded peptides broadly. Both compounds remain available through licensed compounding pharmacies, but regulatory changes could affect access. Users who value regulatory certainty have reason to prefer sermorelin. For context on sermorelin's regulatory history, see is sermorelin a steroid.

This is a gap in most competitor content. The reason Geref (brand sermorelin) was withdrawn matters for users deciding between sermorelin and CJC-1295.

Sermorelin was not withdrawn for safety failures, clinical failures, or post-market adverse event signals. EMD Serono discontinued production due to manufacturing and commercial viability challenges. The pediatric GH deficiency market shifted toward recombinant HGH, which was more profitable and easier to manufacture at scale. Sermorelin's market dried up, not its safety record.

The compound remains available through compounding pharmacies and is prescribed by many longevity and anti-aging physicians. Its prior FDA approval means it has more regulatory documentation than any other peptide currently available through compounding channels. This is a meaningful distinction for safety-conscious users.

Your primary goal determines the better option. The following framework accounts for goals, risk tolerance, and practical preferences.

Stacking CJC-1295 and sermorelin is not standard practice. Both compounds target the GHRH receptor on pituitary somatotrophs. Using two GHRH agonists creates redundancy: the receptor can only respond a set number of times per hour regardless of how many agonists are present.

Productive stacks pair a GHRH analog with a GHRP, activating two distinct receptor pathways for genuine synergy.

For a broader view of how CJC-1295 compares to other GH analogs, see our tesamorelin vs CJC-1295 comparison. For the comprehensive three-way breakdown, see tesamorelin vs sermorelin vs ipamorelin. For stacking strategy, see our peptide stacking guide.